Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) ($M)
Form 10-Q / 10-K Restructuring Footnote
Latest, FY2023
743
Period ended Dec 31, 2023
Change on a year earlier
+11.6%
666 in FY2022
History
3 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 743 | +11.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 666 | -23.3% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 868 | – | Form 10-K (filed 2024-02-26) ↗ |
Breakdown
What makes up 2019 restructuring program (legacy) — total period charges incurred ($m)
- 2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M)597 · FY2023
- 2019 Restructuring Program (legacy) — Recorded in Cost of Sales ($M)149 · FY2023
- 2019 Restructuring Program (legacy) — Recorded in R&D ($M)1 · FY2023
- 2019 Restructuring Program (legacy) — Recorded in Restructuring Line Item ($M)471 · FY2023
Cite this data
StockData. (2026). Merck 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) ($M), annual FY2021–FY2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_program2019_incurred
See every metric in the Merck KPI table. Data updated Oct 26, 2026.